Arrowhead Pharmaceuticals Inc (ARWR)
Pretax margin
| Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -602,260 | -202,491 | -172,278 | -140,846 | -84,551 |
| Revenue | US$ in thousands | 3,471 | 222,409 | 243,231 | 138,287 | 87,992 |
| Pretax margin | -17,351.20% | -91.04% | -70.83% | -101.85% | -96.09% |
September 30, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $-602,260K ÷ $3,471K
= -17,351.20%
Arrowhead Pharmaceuticals Inc's pretax margin has shown significant fluctuations over the past five years. In 2024, the pretax margin stood at -17,351.20%, an improvement compared to the previous year's -91.04% and 2022's -70.83%. However, the company still experienced substantial losses in 2024.
The pretax margin was particularly concerning in 2021 and 2020, where it was reported at -101.85% and -96.09% respectively. This indicates that the company's operating expenses and losses before taxes far exceeded its revenues during these years.
Overall, Arrowhead Pharmaceuticals Inc's pretax margin performance has been volatile and indicates that the company has faced challenges in generating profits and controlling costs. Further analysis of the company's financial health and operational efficiency is recommended to understand the drivers behind these fluctuations.
Peer comparison
Sep 30, 2024